This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
Alexion's (ALXN) Soliris Drives Growth Amid Pricing Pressure
by Zacks Equity Research
Alexion (ALXN) drives growth on consistent demand for lead drug, Soliris. The label expansion of the drug should further propel sales and combat pricing pressure.
Immunomedics Enters Into Supply Deal for Breast Cancer Drug
by Zacks Equity Research
Immunomedics (IMMU) entered into a long-term master supply agreement for lead candidate, sacituzumab govitecan.
Sanofi Wins FDA Nod for Pediatric Hexavalent Combo Vaccine
by Zacks Equity Research
Sanofi (SNY) gains an FDA approval for its pediatric hexavalent combination vaccine, Vaxelis.
Bayer (BAYRY) Faces Generic Threat & Rising Competition
by Zacks Equity Research
Bayer (BAYRY) is facing generic threats/competition for many of its products. The genericization of key drugs will negatively impact revenues.
AbbVie Partners Lupin to Boost Hematological Cancer Pipeline
by Zacks Equity Research
AbbVie (ABBV) enters into partnership with India-based Lupin, gaining exclusive rights to develop and commercialize the latter's investigational MALT1 inhibitors for hematological cancers.
Pfizer/Merck KGaA End Bavencio Ovarian Cancer Phase III Study
by Zacks Equity Research
Pfizer (PFE) and Merck KGaA terminate a late-stage study on Bavencio. This is the second ovarian cancer study failure in less than two months.
Pharma Stock Roundup: GSK, PFE Ink Consumer Health JV, JNJ Hit by Talc Allegations
by Zacks Equity Research
Glaxo (GSK) and Pfizer (PFE) agree to merge their consumer healthcare units into a new JV. J&J stock hit by reports alleging it of being aware of the presence of asbestos in baby powder.
Bristol-Myers to Sell French Consumer Health Unit for $1.6B
by Zacks Equity Research
Bristol-Myers (BMY) receives a $1.6 billion offer for its French consumer health unit from Japanese company, Taisho.
Bristol-Myers Squibb (BMY) Stock Moves -0.65%: What You Should Know
by Zacks Equity Research
In the latest trading session, Bristol-Myers Squibb (BMY) closed at $50.06, marking a -0.65% move from the previous day.
Merck's Keytruda Gets FDA Approval for Rare Skin Cancer
by Zacks Equity Research
Merck (MRK) wins an accelerated approval from the FDA to expand Keytruda's label for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma.
Bristol-Myers' Label Expansion of Sprycel Gets CHMP Nod
by Zacks Equity Research
Bristol-Myers (BMY) gets positive opinion from the CHMP on the label expansion of Sprycel. The company also collaborates with other institutions for developing pipeline.
Merck's Keytruda Gets EU Nod as Adjuvant Therapy for Melanoma
by Zacks Equity Research
Merck (MRK) gains an EU approval for Keytruda as an adjuvant therapy pertaining to adult patients with advanced melanoma.
BMY vs. AZN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
BMY vs. AZN: Which Stock Is the Better Value Option?
Pfizer's (PFE) Biosimilar of Avastin Gets Positive CHMP Nod
by Zacks Equity Research
Pfizer (PFE) gets positive CHMP opinion for Zirabev (bevacizumab), a potential biosimilar to Roche's Avastin (bevacizumab).
Merck to Acquire Europe's Antelliq Group for $2.4 Billion
by Zacks Equity Research
Merck (MRK) secures an acquisition deal to purchase French animal health company Antelliq Group for a consideration of around $2.4 billion.
Lilly (LLY) to Acquire Pain Candidate From Private Biotech
by Zacks Equity Research
Lilly (LLY) inks a deal with privately held Hydra Biosciences to add the latter's pre-clinical pain candidate to its portfolio.
The Zacks Analyst Blog Highlights: Comcast, American Express, Bristol-Myers, T-Mobile and General Motors
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Comcast, American Express, Bristol-Myers, T-Mobile and General Motors
Pharma Stock Roundup: AZN, RHHBY Cancer Drugs, LLY, BMY New Deals in Focus
by Zacks Equity Research
AstraZeneca's (AZN) Imfinzi misses endpoint in study. Roche's (RHHBY) cancer drug combo gets FDA nod for first-line lung cancer. Lilly (LLY) & Bristol Myers (BMY) sign new deals.
Zacks.com featured highlights include: Nexstar Media, Bristol-Myers Squibb, Capital One Financial, Helmerich & Payne and Progressive
by Zacks Equity Research
Zacks.com featured highlights include: Nexstar Media, Bristol-Myers Squibb, Capital One Financial, Helmerich & Payne and Progressive
Top Analyst Reports for Comcast, American Express & Bristol-Myers
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Comcast (CMCSA), American Express (AXP) and Bristol-Myers (BMY).
Bristol-Myers Squibb (BMY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Bristol-Myers Squibb (BMY) closed at $53.64 in the latest trading session, marking a +0.37% move from the prior day.
J&J's Tremfya Beats Novartis' Cosentyx in Head-to-Head Study
by Zacks Equity Research
J&J's (JNJ) psoriasis drug Tremfya proves to be better than Novartis' Cosentyx in phase III head-to-head study for treating adult patients with moderate to severe plaque psoriasis.
Mallinckrodt's Roxicodone Reformulation Gets CRL From FDA
by Zacks Equity Research
Mallinckrodt (MNK) receives complete response letter from the FDA related to its regulatory application seeking approval for abuse-deterrent reformulation of opioid painkiller, Roxicodone.
Upgraded Broker Ratings Make These 5 Stocks Worth a Look Now
by Zacks Equity Research
Following what the majority of brokers are saying about a particular stock can help understand its potential. Hence, when a broker upgrades a stock, one can easily rely on it.
New Strong Buy Stocks for December 13th
by Nitish Marwah
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today: